ArticleScientific reports2025
Synthesis of chitosan/PVA/copper oxide nanocomposite using Anacardium occidentale extract and evaluating its antioxidant, antibacterial, anti-inflammatory and cytotoxic activities.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Capsicum annuum L. oleoresin attenuates complete Freund's adjuvant-induced arthritis through modulation of COX-2-associated inflammation and oxidative stress.Inflammopharmacology · 2026Article
- Marine macroalgae-mediated ultrasonic-assisted green synthesis of CuO nanoparticles embedded in starch/PVA electrospun nanoscaffolds for in vitro α-amylase and α-glucosidase inhibitory activity.Scientific reports · 2026Article
- Plant-Based Nano-Delivery Systems in the Treatment of Inflammatory Disorders.Pharmaceutics · 2026Review
- Recent advances in the delivery of natural-product antioxidants for the treatment of breast cancer.Frontiers in bioengineering and biotechnology · 2026Review
- Insights into structure, toxicity and antibacterial potential of tungsten oxide-carbon nanocomposites coupled with antibiotics.Scientific reports · 2025Article
- Pharmacological and Biological Efficacy of Chitosan-Based Materials.International journal of molecular sciences · 2025Review
- Lactoferrin based copper nanoparticles: a promising anti-cancer strategy against malignant melanoma.Scientific reports · 2025Article
- In vitro biological activities of silver nanoparticles using methanolic leaf extract of Plumeria rubra.Scientific reports · 2025Article
- Biosynthesis of zinc oxide nanoparticles using Moringa oleifera leaf extract, probing antibacterial and antioxidant activities.Scientific reports · 2025Article
- Eco-friendly biosynthesis of silver nanoparticles using marine-derived Fusarium exquisite: optimization, characterization, and evaluation of antimicrobial, antioxidant, and cytotoxic activities.World journal of microbiology & biotechnology · 2025Article
- Biogenic Metal Transformations fromInternational journal of nanomedicine · 2025Article
- Biogenic synthesis of copper oxide nanoparticles usingJournal of oral biology and craniofacial researchArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Nanotechnology has witnessed remarkable advancements in recent years, capturing considerable attention in diverse biomedical applications. Using the green precipitation method, this study aims to synthesize and characterize chitosan/polyvinyl alcohol-copper oxide nanocomposites (CS/PVA/CuONCs) using Anacardium occidentale plant fruit extract. The CS/PVA/CuONCs were further evaluated in antioxidant, antibacterial and biological activities. In our study results, UV-Vis spectrum analysis of CS/PVA/CuONCs revealed a peak at 430 nm. FTIR analyses confirmed the presence of different functional groups, while the XRD study confirmed the crystalline structure of the synthesized nanocomposites. FESEM-EDAX analysis demonstrated that the CS/PVA/CuONCs exhibited a spherical and rod-like shape, with an average particle size of 48.6 to 96.2 nm. Notably, CS/PVA/CuONCs exhibited higher antioxidant activity, as evidenced by their ABTS activity (83.79 ± 1.57%) and SOD activity (86.17 ± 1.28%). In antibacterial assays, CS/PVA/CuONCs demonstrated inhibition in Escherichia coli at 20.52 ± 0.85 mm and Bacillus subtilis at 19.64 ± 0.87 mm, displaying a zone of inhibition. The CS/PVA/CuONCs exhibited excellent anti-inflammatory potency against COX-1 (67.10 ± 0.58%) and COX-2 (76.39 ± 0.65%). The antidiabetic assay revealed excellent α-amylase inhibition (80.25 ± 1.29%) and α-glucosidase inhibition (84.74 ± 1.42%) activities. Anti-cholinergic activity of AChE was 65.35 ± 0.98% and BuChE was 82.46 ± 1.15% are observed. CS/PVA/CuONCs was shown to have strong cytotoxicity against MCF-7 cell lines. It also had the highest cell viability inhibition, at 13.66 ± 0.58%. The hemolysis activity was found to be 5.38 ± 0.34%. Overall, the study demonstrated that CS/PVA/CuONCs possess remarkably excellent biological activities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.